China Medical System: New Drug Application of Desidustat Tablets Accepted in China
April 23, 2024 09:46 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is...
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
April 01, 2024 08:30 ET
|
China Medical System Holdings Ltd.
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo...
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
March 27, 2024 22:09 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013...
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®
February 03, 2024 20:00 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned...
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
January 02, 2024 01:33 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited...
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
December 13, 2023 03:13 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Innovative drugs VALTOCO (Diazepam Nasal Spray)，ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly...
China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China
December 04, 2023 08:28 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new...
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
August 24, 2023 08:00 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic...
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
July 31, 2023 08:00 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, July 31, 2023 (GLOBE NEWSWIRE) -- Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and...
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global
June 29, 2023 08:00 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, June 29, 2023 (GLOBE NEWSWIRE) -- CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global. Nearly 1600 Chinese companies were included in the...